# Omega Therapeutics Inc. (OMGA)

Source: https://www.quantisnow.com/company/OMGA
Generated: 2026-11-06T20:24:07.093Z

- Ticker: OMGA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2021
- Website: omegatherapeutics.com

## About

Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

## Latest OMGA news and filings

- 2025-03-26 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Omega Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-omega-therapeutics-inc-5960186)
- 2025-03-21 20:04 UTC [SEC Form POS AM filed by Omega Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-omega-therapeutics-inc-5955779)
- 2025-03-21 20:03 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Omega Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-omega-therapeutics-inc-5955767)
- 2025-03-20 20:04 UTC [SEC Form 25 filed by Omega Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-25-filed-by-omega-therapeutics-inc-5954207)
- 2025-03-07 14:57 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Omega Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-omega-therapeutics-inc-5932735)
- 2025-02-24 21:48 UTC [SEC Form 8-K] [SEC Form 8-K filed by Omega Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-omega-therapeutics-inc-5905894)
- 2025-02-14 21:59 UTC [SEC Form 8-K] [Omega Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation](https://www.quantisnow.com/insight/omega-therapeutics-inc-filed-sec-form-8-k-entry-into-a-5891508)
- 2025-02-05 21:40 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Omega Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-omega-therapeutics-inc-5873448)
- 2025-02-05 20:57 UTC [SEC Form 144] [SEC Form 144 filed by Omega Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-omega-therapeutics-inc-5872718)
- 2025-02-05 02:59 UTC [SEC Form 3] [SEC Form 3 filed by new insider Varsalone Jeffrey T](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-varsalone-jeffrey-t-5871497)
- 2025-02-03 22:05 UTC [SEC Form 8-K] [Omega Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Leadership Update, Other Events](https://www.quantisnow.com/insight/omega-therapeutics-inc-filed-sec-form-8-k-entry-into-a-5867883)
- 2025-01-28 21:28 UTC [SEC Form 8-K] [SEC Form 8-K filed by Omega Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-omega-therapeutics-inc-5860046)
- 2025-01-23 11:00 UTC [Flagship Pioneering, Cambridge University Health Partners, and Milner Therapeutics Institute Announce Collaboration to Accelerate Biotech Research and Innovation](https://www.quantisnow.com/insight/flagship-pioneering-cambridge-university-health-partners-and-milner-therapeutics-institute-5854286)
- 2025-01-17 22:00 UTC [SEC Form 8-K] [SEC Form 8-K filed by Omega Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-omega-therapeutics-inc-5850304)
- 2025-01-10 21:47 UTC [SEC Form 8-K] [SEC Form 8-K filed by Omega Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-omega-therapeutics-inc-5842241)
- 2024-12-31 22:37 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Omega Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-omega-therapeutics-inc-5828212)
- 2024-12-31 22:30 UTC [SEC Form 8-K] [SEC Form 8-K filed by Omega Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-omega-therapeutics-inc-5828209)
- 2024-12-06 22:00 UTC [SEC Form 8-K] [SEC Form 8-K filed by Omega Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-omega-therapeutics-inc-5804078)
- 2024-12-05 21:10 UTC [SEC Form 4] [SEC Form 4 filed by Director Mehrotra Ravi](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-mehrotra-ravi-5802086)
- 2024-12-05 21:05 UTC [SEC Form 3] [SEC Form 3 filed by new insider Mehrotra Ravi](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-mehrotra-ravi-5802022)
- 2024-11-26 23:31 UTC [SEC Form 4] [SEC Form 4 filed by Chief Scientific Officer Nelson Jennifer Ann](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-scientific-officer-nelson-jennifer-5792602)
- 2024-11-26 23:27 UTC [SEC Form 3] [SEC Form 3 filed by new insider Nelson Jennifer Ann](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-nelson-jennifer-ann-5792596)
- 2024-11-20 13:00 UTC [Leadership Update] [Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies](https://www.quantisnow.com/insight/flagship-pioneering-appoints-angela-hwang-as-ceo-partner-and-chief-executive-5784335)
- 2024-11-20 11:30 UTC [Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer](https://www.quantisnow.com/insight/flagship-pioneering-announces-two-new-agreements-with-ampersand-biomedicines-and-5784147)
- 2024-11-15 23:09 UTC [SEC Form 4] [SEC Form 4 filed by Officer Certel Kaan](https://www.quantisnow.com/insight/sec-form-4-filed-by-officer-certel-kaan-5779505)
- 2024-11-15 14:11 UTC [Analyst Downgrade] [Omega Therapeutics downgraded by Raymond James](https://www.quantisnow.com/insight/omega-therapeutics-downgraded-by-raymond-james-5778336)
- 2024-11-14 21:16 UTC [SEC Form 8-K] [Omega Therapeutics Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/omega-therapeutics-inc-filed-sec-form-8-k-other-events-5776087)
- 2024-11-14 21:05 UTC [Leadership Update] [Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results](https://www.quantisnow.com/insight/omega-therapeutics-announces-successful-completion-of-phase-1-trial-for-5775485)
- 2024-11-14 21:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Omega Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-omega-therapeutics-inc-5775335)
- 2024-11-13 13:00 UTC [Leadership Update] [Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio](https://www.quantisnow.com/insight/flagship-pioneering-appoints-craig-williams-as-ceo-partner-and-chief-executive-5770037)
- 2024-11-13 13:00 UTC [Leadership Update] [Brian M. Alexander Joins Valo Health as Chief Executive Officer and Flagship Pioneering as CEO-Partner](https://www.quantisnow.com/insight/brian-m-alexander-joins-valo-health-as-chief-executive-officer-5770035)
- 2024-10-23 12:00 UTC [Leadership Update] [Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence](https://www.quantisnow.com/insight/flagship-pioneering-announces-appointment-of-junaid-bajwa-as-senior-partner-5734517)
- 2024-10-15 12:00 UTC [Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings](https://www.quantisnow.com/insight/omega-therapeutics-to-present-multiple-posters-highlighting-versatile-platform-capabilities-5724733)
- 2024-10-09 11:00 UTC [Leadership Update] [Flagship Pioneering Announces Appointment of Paul Parker as Managing Partner, Leading Capital Solutions](https://www.quantisnow.com/insight/flagship-pioneering-announces-appointment-of-paul-parker-as-managing-partner-5720406)
- 2024-10-04 21:10 UTC [SEC Form 4] [SEC Form 4 filed by Director Rosiello Robert L.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-rosiello-robert-l-5717378)
- 2024-10-04 21:01 UTC [SEC Form 3] [SEC Form 3 filed by new insider Rosiello Robert L.](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-rosiello-robert-l-5717340)
- 2024-10-04 21:00 UTC [SEC Form 8-K] [Omega Therapeutics Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/omega-therapeutics-inc-filed-sec-form-8-k-leadership-update-5717328)
- 2024-10-03 12:00 UTC [Leadership Update] [Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors](https://www.quantisnow.com/insight/invaio-sciences-appoints-andr-andonian-as-chairman-of-the-board-5714395)
- 2024-10-03 01:00 UTC [A*STAR and Flagship Pioneering Announce Partnership to Spur Biotech Innovation in Singapore](https://www.quantisnow.com/insight/astar-and-flagship-pioneering-announce-partnership-to-spur-biotech-innovation-5714076)
- 2024-10-01 12:30 UTC [Leadership Update] [Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer](https://www.quantisnow.com/insight/halda-therapeutics-appoints-veteran-biopharma-leader-christian-schade-as-president-5709624)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/OMGA
- Earnings history: https://www.quantisnow.com/earnings/OMGA
- Dividend history: https://www.quantisnow.com/dividends/OMGA
- Insider transactions: https://www.quantisnow.com/insiders/OMGA
- Options chain: https://www.quantisnow.com/options/OMGA
- SEC 8-K filings only: https://www.quantisnow.com/company/OMGA/8-k
- RSS and alerts for OMGA: https://www.quantisnow.com/docs/rss-feeds.md